Physician profile
Anup Patel
NPI 1942391842
$24,662.78
in general payments reported to CMS, 2019-2025
12 companies · $9,060 in 2025
The $9,060 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.79 · 2020: $29.85 · 2022: $6,421 · 2024: $9,103 · 2025: $9,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $515 · Travel and Lodging: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,398.75 |
| Food and Beverage | $514.58 |
| Travel and Lodging | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19,719.24 | 2022-2025 | Prevymis |
| Veloxis Pharmaceuticals, INC. | $4,834.60 | 2019-2022 | |
| Daiichi Sankyo INC. | $29.98 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.63 | 2025 | Livtencity |
| Astrazeneca Pharmaceuticals LP | $16.96 | 2024 | Farxiga |
| Smith+Nephew, INC. | $14.93 | 2019 | |
| Astellas Pharma Global Development | $14.86 | 2020 | |
| Sebela Pharmaceuticals INC. | $12.58 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anup Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.